Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055157 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02055157 is a Phase 2 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 35 participants.
The verdict
NCT02055157, a Phase 2 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
Interventions
- DRUG BMN 111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-01-13 |
| Est. Completion | 2017-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055157
The ClinicalTrials.gov registry entry for NCT02055157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMN 111 is the first listed.
NCT02055157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02055157 about?
NCT02055157 is a clinical study titled "A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia". This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
What is the current status of trial NCT02055157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-01-13. Estimated completion is 2017-10-02.
What interventions are being tested in trial NCT02055157?
The interventions under investigation include: BMN 111 (DRUG).
Who is sponsoring clinical trial NCT02055157?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.